Alexander E Barkas Net Worth

The estimated Net Worth of Alexander E Barkas is at least 244 千$ dollars as of 5 June 2007. Alexander Barkas owns over 6,427 units of Geron stock worth over 147,539$ and over the last 21 years Alexander sold GERN stock worth over 96,405$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Alexander Barkas GERN stock SEC Form 4 insiders trading

Alexander has made over 1 trades of the Geron stock since 2007, according to the Form 4 filled with the SEC. Most recently Alexander sold 6,427 units of GERN stock worth 96,405$ on 5 June 2007.

The largest trade Alexander's ever made was selling 6,427 units of Geron stock on 5 June 2007 worth over 96,405$. On average, Alexander trades about 321 units every 0 days since 2003. As of 5 June 2007 Alexander still owns at least 33,608 units of Geron stock.

You can see the complete history of Alexander Barkas stock trades at the bottom of the page.

What's Alexander Barkas's mailing address?

Alexander's mailing address filed with the SEC is C/O PROSPECT VENTURE PARTNERS, 435 TASSO STREET, SUITE 200, PALO ALTO, CA, 94301.

Insiders trading at Geron

Over the last 21 years, insiders at Geron have traded over 2,393,273$ worth of Geron stock and bought 340,678 units worth 567,384$ . The most active insiders traders include John A Scarlett、Daniel Bradbury、Stephen Rosenfield. On average, Geron executives and independent directors trade stock every 93 days with the average trade being worth of 587,812$. The most recent stock trade was executed by Andrew J Grethlein on 8 July 2024, trading 674,348 units of GERN stock currently worth 1,159,879$.

What does Geron do?

we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.

Complete history of Alexander Barkas stock trades at Amicus Therapeutics Inc、Geron

Geron executives and stock owners

Geron executives and other stock owners filed with the SEC include:

• John Scarlett,
  Chairman of the Board, President, Chief Executive Officer
• Aleksandra Rizo,
  Executive Vice President, Chief Medical Officer
• Dr. John A. Scarlett,
  CEO, Pres & Chairman
• Stephen Rosenfield,
  Executive Vice President, Corporate Secretary, Chief Legal Officer
• Andrew Grethlein,
  Executive Vice President, Chief Operating Officer
• Olivia Bloom,
  Chief Financial Officer, Executive Vice President - Finance, Treasurer
• Melissa Kelly Behrs,
  Executive Vice President, Chief Business Officer
• Dr. Aleksandra Rizo M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Dr. Andrew J. Grethlein,
  Exec. VP & COO
• Melissa A. Kelly Behrs,
  Exec. VP of Bus. Operations & Chief Alliance Officer
• Olivia Kyusuk Bloom,
  Exec. VP of Fin., CFO & Treasurer
• Elizabeth O'Farrell,
  Independent Director
• Dawn Bir,
  Independent Director
• Karin Eastham,
  Lead Independent Director
• V. Bryan Lawlis,
  Independent Director
• Robert Spiegel,
  Independent Director
• Susan Molineaux,
  Independent Director
• Anil Kapur,
  Executive Vice President, Corporate Strategy and Chief Commercial Officer
• Edward E. Koval,
  Exec. VP & Chief Bus. Officer
• Anil Kapur,
  Chief Commercial Officer & Exec. VP of Corp. Strategy
• Stephen N. Rosenfield,
  Exec. VP, Chief Legal Officer & Corp. Sec.
• Shannon Odam,
  VP of HR
• Suzanne Messere,
  Head of Investor Relations & Corp. Communications
• Daniel Bradbury,
  Director
• Thomas Hofstaetter,
  Director
• Hoyoung Huh,
  Director
• James Ziegler,
  EVP, Chief Commercial Officer
• Gaurav Aggarwal,
  
• Calvin Harley,
  Chief Scientific Officer
• Graham K Cooper,
  EVP, Bus Dev & CFO
• Katharine E. Spink,
  VP Operations, Regen Med Progs
• Jane Lebkowski,
  VP Regenerative Medicine
• David Greenwood,
  SVP Corporate Development and
• Melanie I Nallicheri,
  SVP Corp Dev
• Alexander E Barkas,
  Director
• Charles J Homcy,
  Director
• Thomas Okarma,
  President and CEO
• Patrick J Zenner,
  Director
• Fabio M Benedetti,
  SVP, Chief Med Off, Oncology
• John Peter Walker,
  Director
• Alan Colowick,
  President, Oncology
• Robert B Stein,
  Director
• Stephen Michael Kelsey,
  EVP, CMO, Oncology
• Edward V Fritzky,
  Director
• Craig C Parker,
  SVP, Corporate Development
• David Earp,
  VP Intellectual Property
• Thomas Kiley,
  Director
• Bioscience Inc Merix,
  10% owner
• William Stempel,
  VP and General Counsel
• John F Mc Donald,
  
• Faye Feller,
  EVP, Chief Medical Officer
• Scott Alan Samuels,
  EVP, Chief Legal Officer
• Michelle Robertson,
  EVP, Chief Financial Officer